<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621331</url>
  </required_header>
  <id_info>
    <org_study_id>FGN-PED-CLIN-02</org_study_id>
    <nct_id>NCT04621331</nct_id>
  </id_info>
  <brief_title>Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD</brief_title>
  <official_title>An Open-label, Multicenter Study Investigating the Efficacy, Safety and Pharmacokinetics of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-labeled, multicenter study is designed to evaluate the efficacy, safety and PK/PD&#xD;
      of roxadustat in ESA-naïve and ESA-treated pediatric patients with CKD Stages 3, 4, and 5, as&#xD;
      well as end-stage renal disease (ESRD) who are receiving either hemodialysis (HD) or&#xD;
      peritoneal dialysis (PD). The study will enroll patients between the ages of 2 to &lt;18 years&#xD;
      in two sequential cohorts, with the older cohort of ages 12 to &lt;18 years enrolled first.&#xD;
      Approximately 30 patients will be enrolled in each age-based cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with mean Hb ≥ 11.0 g/dL</measure>
    <time_frame>Averaged over weeks 16-24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in Hb</measure>
    <time_frame>Baseline to averaged over weeks 16-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first Hb response (this only applies to NDD patients)</measure>
    <time_frame>From baseline without rescue therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anemia Associated With Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Roxadustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting doses of 20, 50, 70 or 100 mg based on weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat</intervention_name>
    <description>HIF-PH inhibitor for treatment of anemia in CKD</description>
    <arm_group_label>Roxadustat</arm_group_label>
    <other_name>FG-4592</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Important Inclusion Criteria:&#xD;
&#xD;
          -  Clinically stable CKD in the opinion of the investigator.&#xD;
&#xD;
          -  Estimated glomerular filtration rate (Bedside Schwartz formula) of &lt; 60 ml/min/1.73 m2&#xD;
             (stage 3, 4 and 5 CKD) for non-dialysis patients, or patients who are receiving&#xD;
             chronic dialysis (hemodialysis or peritoneal dialysis) for ESRD.&#xD;
&#xD;
          -  For ESA-naïve patients (either NDD or DD; ESA-naïve is defined as those patients whose&#xD;
             total duration of prior ESA exposure is ≤ 3 weeks within the preceding 12 weeks at the&#xD;
             time informed consent is obtained), mean of two most recent central laboratory Hb&#xD;
             values during the screening period obtained at least 2 days apart must be &lt; 11.0 g/dL.&#xD;
             For patients currently receiving stable ESA dosing who will discontinue ESA and&#xD;
             convert to roxadustat during study, mean of two most recent central laboratory Hb&#xD;
             values during the screening period obtained at least 2 days apart must be ≥ 10.0 g/dL&#xD;
             and ≤ 12.5 g/dL.&#xD;
&#xD;
          -  Ferritin &gt;50 ng/mL and transferrin saturation &gt;10% (obtained from screening visit).&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2x upper limit&#xD;
             of normal (ULN) and total bilirubin (Tbili) ≤1.5x ULN at randomization (obtained from&#xD;
             screening visit).&#xD;
&#xD;
          -  Serum folate and vitamin B12 &gt; LLN (obtained from screening visit).&#xD;
&#xD;
        Important Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled hypertension as judged by the principal investigator in the 2 weeks prior&#xD;
             to screening.&#xD;
&#xD;
          -  Known hematologic disease other than anemia associated with CKD.&#xD;
&#xD;
          -  Known malignancy within the past 5 years before screening.&#xD;
&#xD;
          -  Any prior organ transplant or any planned organ transplant during the study period.&#xD;
&#xD;
          -  Any RBC transfusion during the past 8 weeks before screening.&#xD;
&#xD;
          -  Any condition leading to significant blood loss (e.g., gastrointestinal bleeding,&#xD;
             surgical procedures) within 8 weeks before screening or during the screening period.&#xD;
&#xD;
          -  History of chronic liver disease.&#xD;
&#xD;
          -  Pure red cell aplasia (PRCA) or history of PRCA.&#xD;
&#xD;
          -  History of epileptic seizures.&#xD;
&#xD;
          -  History of hyperlipidemia or significant thrombotic/thromboembolic event (e.g., deep&#xD;
             vein thrombosis, pulmonary embolism, stroke, myocardial infarction).&#xD;
&#xD;
          -  History of thrombosis of an arteriovenous fistula/graft within 12 weeks prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Any active systemic or significant infection or episode of peritonitis within 30 days&#xD;
             of screening.&#xD;
&#xD;
          -  Any statin use within 30 days of screening.&#xD;
&#xD;
          -  Any prior exposure to roxadustat or any other HIF-PH inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Will Chou</last_name>
    <phone>650.296.6754</phone>
    <email>wchou@Fibrogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Priya Verghese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Melissa Muff-Luett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hilary Hotchkiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beneta Parthiban</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia, Chronic Kidney Disease (CKD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

